Cargando…

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Xinxin, Zhou, Zhuan, Kang, Rui, Tang, Daolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629117/ https://www.ncbi.nlm.nih.gov/pubmed/36338145 http://dx.doi.org/10.1080/2162402X.2022.2141978

Ejemplares similares

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
por: Tang, Daolin, et al.
Publicado: (2021)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Anderson, John, et al.
Publicado: (2023)

The Emerging Role of Deubiquitinases in Cell Death
por: Zhou, Zhuan, et al.
Publicado: (2022)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer
por: Manabe, Tadashi, et al.
Publicado: (2022)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
por: Ahmed, Mahiuddin, et al.
Publicado: (2015)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Not so WEE: Targeting G(2)/M to kill mesothelioma cells
por: Dent, Paul
Publicado: (2014)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

HSP90 as an emerging barrier to immune checkpoint blockade therapy
por: Tang, Daolin, et al.
Publicado: (2022)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer
por: Cavagna, Rodrigo, et al.
Publicado: (2021)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic
por: Tang, Daolin, et al.
Publicado: (2023)

Cell-type specific potent Wnt signaling blockade by bispecific antibody
por: Lee, Nam-Kyung, et al.
Publicado: (2018)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
por: Passariello, Margherita, et al.
Publicado: (2019)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
por: Weth, R, et al.
Publicado: (2004)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cfqqnle2crot97m3h3tvq7idpk